Results 201 to 210 of about 61,456 (351)

Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease [PDF]

open access: bronze, 2004
Timothy S. Olson   +10 more
openalex   +1 more source

Prognosis of pediatric‐onset inflammatory bowel disease associated with primary sclerosing cholangitis: A population‐based study

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives To assess whether the prognosis of pediatric‐onset inflammatory bowel disease (IBD) is influenced by its association with primary sclerosing cholangitis (PSC) considering medical treatment, bowel resection, risk of cancer, and mortality. Methods A retrospective population‐based study was conducted using data from the EPIMAD Registry,
Marie‐Laura Godet   +10 more
wiley   +1 more source

Crohn Disease and Possible Infectious Etiologies

open access: bronze, 2002
Jennifer E. Ballard Dwan   +5 more
openalex   +1 more source

Pediatric endoscopic mucosal resection: A 10‐year single‐center experience

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
ABSTRACT Objectives Endoscopic mucosal resection (EMR) is well established in adult gastroenterology but remains underutilized in pediatrics due to limited data, training opportunities, and equipment. This study presents a 10‐year, single‐center experience with conventional hot and cold snare EMR, band‐assisted (B‐EMR), and underwater EMR (U‐EMR ...
Brett J. Hoskins   +2 more
wiley   +1 more source

Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn disease [PDF]

open access: bronze, 2004
Keiko Yamazaki   +8 more
openalex   +1 more source

A significant number of pediatric inflammatory bowel disease patients are exposed to a medication not approved by the Food and Drug Administration for pediatric use

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Inflammatory bowel disease (IBD) presents before age 20 years in ~25% of patients. Regulatory approvals of IBD medications for pediatric use are often delayed. Nevertheless, many pediatric patients receive medication not approved for pediatric use.
Courtney Rusch   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy